Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma - PubMed (original) (raw)
. 2001 May 15;47(3):183-8.
doi: 10.1002/pros.1061.
Affiliations
- PMID: 11351347
- DOI: 10.1002/pros.1061
Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma
A J O'Neill et al. Prostate. 2001.
Abstract
Background: Apoptotic resistance to androgen ablation represents a significant problem in the treatment of prostate cancer. Over expression of antiapoptotic proteins such as Bcl-2 and mutations in p53 contribute to this resistance. The caspase family of proteases are central executioners of the cell death pathway. They are expressed in normal prostate secretory epithelial cells. Altered expression may represent an additional component leading to cell resistance. The aim of this study was to determine by immunohistochemistry caspase 3 expression in benign prostatic hyperplasia and prostate cancers.
Methods: Twenty-two patients with histologically determined prostate cancer and benign prostatic hyperplasia (BPH) were investigated. All specimens were obtained from patients undergoing surgical resection of the prostate. Immunohistochemical analysis was performed on formalin fixed paraffin embedded sections to assess caspase 3 expression.
Results: Caspase 3 was expressed in 18/22 (81.1%) samples, with high expression in BPH which demonstrated staining in both basal and secretory epithelial cells. Increasing grades of prostatic cancer showed a significant loss of expression in secretory epithelial layers and little staining in epithelial cells in high-grade prostatic carcinoma.
Conclusions: Altered caspase 3 expression may represent an additional mechanism of apoptotic resistance to androgen ablation. Prostate 47:183-188, 2001.
Copyright 2001 Wiley-Liss, Inc.
Similar articles
- Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia.
Hu XY, Xu YM, Chen XC, Ping H, Chen ZH, Zeng FQ. Hu XY, et al. APMIS. 2006 Dec;114(12):893-8. doi: 10.1111/j.1600-0463.2006.apm_271.x. APMIS. 2006. PMID: 17207090 - [Expression and significance of caspase-1 in benign hyperplastic prostate tissues].
Deng CH, Zang ZJ, Sun XZ, Huang XH, Wang H, Wang D, Su SH. Deng CH, et al. Zhonghua Nan Ke Xue. 2005 Nov;11(11):810-2. Zhonghua Nan Ke Xue. 2005. PMID: 16333955 Chinese. - Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
Royuela M, de Miguel MP, Ruiz A, Fraile B, Arenas MI, Romo E, Paniagua R. Royuela M, et al. Eur Cytokine Netw. 2000 Mar;11(1):119-27. Eur Cytokine Netw. 2000. PMID: 10705309 - [Gene regulation of prostaglandin synthase and prostate diseases].
Wu SS, Wu JH, Sun ZY. Wu SS, et al. Zhonghua Nan Ke Xue. 2017 Jul;23(7):663-667. Zhonghua Nan Ke Xue. 2017. PMID: 29723463 Review. Chinese. - Regulation of apoptosis in prostatic disease.
Thompson TC, Yang G. Thompson TC, et al. Prostate Suppl. 2000;9:25-8. doi: 10.1002/1097-0045(2000)45:9+<25::aid-pros6>3.0.co;2-5. Prostate Suppl. 2000. PMID: 11056499 Review.
Cited by
- Apoptosis-Cell Cycle-Autophagy Molecular Mechanisms Network in Heterogeneous Aggressive Phenotype Prostate Hyperplasia Primary Cell Cultures Have a Prognostic Role.
Matei E, Enciu M, Roșu MC, Voinea F, Mitroi AF, Deacu M, Băltățescu GI, Nicolau AA, Chisoi A, Aşchie M, Ionescu Mitu AC. Matei E, et al. Int J Mol Sci. 2024 Aug 28;25(17):9329. doi: 10.3390/ijms25179329. Int J Mol Sci. 2024. PMID: 39273277 Free PMC article. - Integrated aerobic exercise with LDE-docetaxel treatment: a novel approach to combat prostate cancer progression.
Veras ASC, Batista VRG, Correia RR, de Almeida Tavares ME, Rubira RJG, Tavares ER, Giometti IC, Maranhão RC, Teixeira GR. Veras ASC, et al. Sci Rep. 2024 Apr 26;14(1):9626. doi: 10.1038/s41598-024-60138-y. Sci Rep. 2024. PMID: 38671015 Free PMC article. - Growth and Migration Blocking Effect of Nanaomycin K, a Compound Produced by Streptomyces sp., on Prostate Cancer Cell Lines In Vitro and In Vivo.
Hirata Y, Shigemura K, Moriwaki M, Iwatsuki M, Kan Y, Ooya T, Maeda K, Yang Y, Nakashima T, Matsuo H, Nakanishi J, Fujisawa M. Hirata Y, et al. Cancers (Basel). 2023 May 10;15(10):2684. doi: 10.3390/cancers15102684. Cancers (Basel). 2023. PMID: 37345021 Free PMC article. - Immunohistochemical Evaluation of PARP and Caspase-3 as Prognostic Markers in Prostate Carcinomas.
Acar V, Couto Fernandez FL, Buscariolo FF, Novais AA, Matheus Pereira RA, de Campos Zuccari DAP. Acar V, et al. Clin Med Res. 2021 Dec;19(4):183-191. doi: 10.3121/cmr.2021.1607. Clin Med Res. 2021. PMID: 34933951 Free PMC article. - The Effect of Exogenous Superoxide Dismutase (SOD) on Caspase-3 Activation and Apoptosis Induction in Pc-3 Prostate Cancer Cells.
Ismy J, Sugandi S, Rachmadi D, Hardjowijoto S, Mustafa A. Ismy J, et al. Res Rep Urol. 2020 Oct 27;12:503-508. doi: 10.2147/RRU.S271203. eCollection 2020. Res Rep Urol. 2020. PMID: 33150140 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous